Finally, Table 2 provides a comparative overview of all anti-GM-CSF mAbs currently evaluated for the treatment of RA, summarizing their clinical efficacy, safety profiles, and key trial outcomes. The gene discussed is CSF2; the disease is rheumatoid arthritis.